[1]De Caterina, R，et al. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. J. Clin. Med. 2021, 10, 573.
[2]Guo, X., Du, J., Yang, Y. et al. Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry. Sci Rep 14, 2778 (2024). https://doi.org/10.1038/s41598-024-51776-3
[3]Doralisa Morrone,et al.Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across all age groups: Two-year results from ETNA-AF.EHRA 2021.
[4]Christian T Ruff , et al.Comparison of the effi cacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.Lancet 2014; 383: 955-62
[5]Xueyuan Guo,et al.Clinical Outcomes of Edoxaban Treatment in Atrial Fibrillation Patients with High Bleeding Risk:Insights from the ETNA-AF-China 1-Year Follow-up.ESC 2024
[6]Robert P. Giugliano,et al.Edoxaban versus Warfarin in Patients with Atrial Fibrillation.N Engl J Med 2013;369:2093-104.
[7]Stefano Fumagalli,et al.Edoxaban dose,frailty,and outcomes in patients with atrial fibrillation:the ETNA-AF-Europe 4-year follow-up.ESC 2024.
